[Skip to Content]
[Skip to Content Landing]
Views 716
Citations 0
Research Letter
September 23, 2019

Treatment for Nicotine Use Disorder Among Medicaid-Enrolled Adolescents and Young Adults

Author Affiliations
  • 1Adolescent Substance Use and Addiction Program, Division of Developmental Medicine, Department of Pediatrics, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts
  • 2Division of Adolescent Medicine, Department of Pediatrics, Sainte-Justine University Hospital Centre, University of Montreal, Montreal, Quebec, Canada566633
  • 3Department of Analytics, Children’s Hospital Association, Lenexa, Kansas
  • 4Boston University School of Public Health, Boston, Massachusetts
  • 5Center for Health Services & Society, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, Los Angeles
  • 6Section of General Internal Medicine, Department of Medicine and Division of General Pediatrics, Department of Pediatrics, Boston Medical Center, Boston University School of Medicine, Boston, Massachusetts
  • 7Division of General Pediatrics, Department of Pediatrics, Boston University School of Medicine, Boston, Massachusetts
JAMA Pediatr. 2019;173(11):1103-1105. doi:10.1001/jamapediatrics.2019.3200

Adolescents and young adults are particularly vulnerable to nicotine’s addictive properties. Decades of decreasing tobacco use are threatened by the rising popularity of e-cigarettes, use of which predicts transition to combustible cigarettes among adolescents and young adults.1 Given rates of tobacco use that remain high among youth, timely data are needed on the extent to which adolescents and young adults with nicotine use disorder (NUD) receive evidence-based treatment with counseling and pharmacotherapy.2

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words